Introduction
============

It is well acknowledged that colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide and also associated with high morbidity and mortality.[@b1-ott-10-2367] Although the treatment for CRC has achieved advances to some extent in recent decades, some patients with CRC often experience recurrence and the clinical results of conventional chemotherapies are still unsatisfactory.[@b2-ott-10-2367] Currently, with self-renewal and pluripotency as well as differentiation, cancer stem cells (CSCs) are identified as a source of malignant tumors, responsible for tumor aggressiveness and recurrence.[@b3-ott-10-2367],[@b4-ott-10-2367] And specially, new therapies targeting CRC cancer stem cells (CRC-CSCs) may markedly raise clinical treatment of CRC to a higher level.[@b5-ott-10-2367],[@b6-ott-10-2367]

Much work during the past years has been done to reveal that a large portion of the human genome is universally transcribed into noncoding RNAs (ncRNAs). Long noncoding RNAs (lncRNAs) are the RNA molecules larger than 200 nucleotides with no protein-coding capacity.[@b7-ott-10-2367],[@b8-ott-10-2367] Recently, lncRNAs expression and their functional mechanisms in tumors have aroused great attention, and numerous cancer-related lncRNAs have been discovered, such as HIF-1 and linc-RoR.[@b9-ott-10-2367] In addition, some lncRNAs have also been identified to be closely associated with stem cell properties such as pluripotency and differentiation.[@b10-ott-10-2367],[@b11-ott-10-2367] Nevertheless, only a few attempts have been made to investigate CSC-related lncRNAs.[@b12-ott-10-2367]

In our previous research work, lncRNA microarray assay was performed on CRC cell lines with the same genetic background but different stem cell properties (data not published). Through bioinformatic analysis, several lncRNAs have been characterized by being connected with CRC-CSC properties. Among them, we explored a potential lncRNA named AC105461.1 (data from UCSC website; <http://genome.ucsc.edu/cgi-bin/hgTracks?db=hg19&lastVirtModeType=default&lastVirtModeExtraState=&virtModeType=default&virtMode=0&nonVirtPosition=&position=chr2%3A232843265%2D232880417&hgsid=589177787_1PUInTrhbGUiWHLTwt9euHndDLwR>). AC105461.1 (ENSG00000227033) starts at 231,978,488 base pair (bp) from pter and ends at 232,015,720 bp from pter, which is located at chr2 (q37.1) on the upstream side of DIS3 mitotic control homolog (*Saccharomyces cerevisiae*)-like 2 (DIS3L2) and DIS3L2 is also the antisense transcript of it. According to GeneCards (<http://www.genecards.org/>), both AC105461.1 and DIS3L2 are upregulated in normal colons. Furthermore, they have certain common transcription factors in the corresponding enhancer region, such as EP300, PHF8, POLR2A, and SIN3A.

Generally, the expression and function of lncRNAs are associated with adjacent protein coding transcripts.[@b13-ott-10-2367],[@b14-ott-10-2367] Massive lncRNA transcripts emanate from transcription at promoters or other nearby locations of protein-coding genes. As "lncRNA/messenger RNA (mRNA) gene pair", the interaction between them is associated with stem cell properties.[@b15-ott-10-2367] DIS3L2 belongs to a family of related 3′--5′ exonucleases with similar domain organization to bacterial RNase II.[@b16-ott-10-2367] According to GeneCards, one of the functions for DIS3L2 is to mediate the degradation of uridylated pre-let-7 miRNAs, contributing to the maintenance of embryonic stem cells. Intriguingly, a new research demonstrates that DIS3L2 is a new component of the Lin28/let-7 pathway and relevant to Perlman syndrome and cancer.[@b17-ott-10-2367] Moreover, emerging evidence indicates that Lin28 could promote colon cancer progression and metastasis by upregulating stem cell-related genes or cooperating with WNT signaling.[@b18-ott-10-2367],[@b19-ott-10-2367]

Therefore, it is tempting to speculate that lncRNA-AC105461.1 may regulate the stem cell-like characteristics of CRC-CSCs by regulating DIS3L2. In the present study, we firstly investigated the expression of AC105461.1 in CRC tissue samples. Next, we explored the expression patterns of the lncRNA/mRNA gene pair between AC105461.1 and DIS3L2 in 47 CRC specimens. Additionally, SW620 and SW480 cells were selected as our candidate cell lines for AC105461.1 overexpression and knockdown experiments. Importantly, cell proliferation assay, matrigel invasion assay, and spheroid formation as well as flow cytometry analysis were performed respectively to investigate the effect of AC105461.1 overexpression or knockdown on stem cell-like properties in vitro.

Materials and methods
=====================

Patient samples
---------------

Patients with CRC (n=47) who underwent initial surgery in the Chinese People's Liberation Army (PLA) General Hospital from 2011 to 2012 were selected for this study. Clinical pathology information of all the samples is summarized in [Table 1](#t1-ott-10-2367){ref-type="table"}. None of the patients received preoperative therapy such as radiotherapy or chemotherapy prior to surgical resection. The utilization of tumor material for research was approved by the ethical committee of PLA General Hospital. Written informed consent was signed by each participant before tumor sample collection.

Cancer cell lines
-----------------

Human CRC cell lines SW620, SW480, HT29, HCT116, and Caco-2 derived from normal human colon were all acquired from the American Type Culture Collection (ATCC; Manassas, VA, USA). The SW620 and SW480 cells were cultured in Leibovitz's L-15 Medium (Thermo Fisher Scientific, Waltham, MA, USA) and the other CRC cell lines were cultured in Dulbecco's Modified Eagle's Medium (DMEM) medium (Thermo Fisher Scientific). All these media contained 10% fetal bovine serum (Thermo Fisher Scientific) and were maintained at 37°C with 5% CO~2~. CSCs in SW620 and SW480 were enriched for CSC-related experiments. The SW620 and SW480 cells were transferred into the stem cell-culturing medium, serum-free DMEM/F12 medium, which consists of 20 ng/mL human epidermal growth factor (Peprotech Inc, Rocky Hill, NJ, USA), 20 ng/mL human basic fibroblast growth factor (Peprotech Inc), and 1% N~2~ supplement (Thermo Fisher Scientific).

Quantitative real-time polymerase chain reaction (PCR)
------------------------------------------------------

Total RNA was extracted from CRC tumor tissues and matched adjacent normal tissues, using Trizol Total RNA Reagent (Thermo Fisher Scientific) following the manufacturer's protocol. The first strand complementary DNAs (cDNAs) were synthesized with 2 μg total RNAs by means of RevertAidTM H Minus First Strand cDNA Synthesis Kit (Takara, Otsu, Japan). The primer sequences were designed and synthesized by GenePharma (Shanghai, People's Republic of China). Quantitative real-time PCR was performed using the SYBR PrimeScript RT-PCR kit (Takara) using Applied Biosystems 7500 Fluorescent Quantitative PCR System (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's recommendations. The reaction conditions were designed as follows: 1 cycle at 95°C for 30 seconds followed by 40 cycles at 95°C for 5 seconds, and 60°C for 34 seconds. The ΔΔCT calculation with CT served as the threshold cycle for quantification of gene expression, and the target gene expression level in patients was measured as "ratio (target in tumor tissue/target in nontumorous tissue": R (T/N)). All reactions were performed in triplicate and normalized by the internal control products of GAPDH. All sequences we used are listed in [Table 2](#t2-ott-10-2367){ref-type="table"}.

Transfection of small interfering RNA (siRNA)
---------------------------------------------

For siRNA analysis, siRNA for the AC105461.1 sequence and non-targeting siRNA were obtained from GenePharma. The sequences are listed in [Table 3](#t3-ott-10-2367){ref-type="table"}. Prior to transfection, approximately 5% SW620 and SW480 cells were plated into 12-well plates and cultured for at least 24 hours to achieve a confluence of 30%--50%. SiRNA transfection was conducted using X-treme GENE™ transfection reagent (Hoffman-La Roche Ltd, Basel, Switzerland) following the manufacturer's instructions. After transfection, cells were harvested for cell proliferation assay, matrigel invasion assay, and spheroid formation assay.

Overexpression of AC105461.1 in CRC cells
-----------------------------------------

The AC105461.1 low-expressed SW620 cells were selected to be transfected with plasmid complementary DNA (pcDNA)-AC105461.1 by Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer's instructions. AC105461.1 cDNA was cloned into BamHI-EcoRI sites of pcDNA3.1. Those transfected cells were harvested for RNA isolation, cell proliferation assay, matrigel invasion assay, spheroid formation assay, and flow cytometry analysis.

Cell proliferation assay
------------------------

According to the manufacturer's instruction, cell proliferation ability was measured by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay (Promega, Madison, WI, USA) after transfection. The SW620 and SW480 cells were plated separately in 96-well at a density of 2,000 cells per well after transfection. Each well containing 100 μL culture medium was added 20 μL of the MTS reagent. The plate was incubated for 2 hours at 37°C in a humidified, 5% CO~2~ atmosphere. Afterward, the plate was read at 490 nm using a plate reader.

Matrigel invasion assay
-----------------------

Transwell assay was performed to observe the cells' invasion ability, and it was conducted using modified Boyden Chambers, which consisted of transwell-precoated matrigel membrane filter with 8 mm pores inserting in 24-well tissue culture plates (BD Biosciences, San Jose, CA, USA). DMEM supplemented with 10% inactivated fetal bovine serum was used as chemoattractant in the lower chamber. Cells that had migrated through the filter were stained and counted at regular intervals. The mean migration rate was calculated as the increasing radius of the entire cell population over time.

Spheroid formation assay
------------------------

Based on ultralow attachment surface 96-well culture plates (Corning Incorporated, Corning, NY, USA), spheroid formation assay was carried out to evaluate the capability of cell self-renewal. Cells in the pcDNA-AC105461.1 and pcDNA control, or in the AC105461.1 siRNAs and negative control siRNA (NC-si) were respectively resuspended in 200 μL serum-free medium DMEM/F12 at a density of 200 cells per well. DMEM/F12 was supplemented with 20 ng/mL human epidermal growth factor, 20 ng/mL human basic fibroblast growth factor, and 1% N~2~. Phase-contrast images were conducted 7 days later.

Flow cytometry analysis
-----------------------

Cells prepared for analyzing the cell surface markers were plated at 60% confluence the day before analysis. Trypsinized cells were washed by phosphate buffered saline, resuspended in 1% bovine serum albumin plus corresponding fluorophore-conjugated primary antibodies, and then incubated for 30 minutes at room temperature. Afterward, the expression of CD133 and CD44 in cultured cells was analyzed by flow cytometry (BD Biotechnology). CD44 and CD133 in SW480 or SW620 cells were respectively sorted by fluorescence-activated cell sorter to obtain CD133^+^CD44^+^, CD133^+^CD44^−^, CD133^−^CD44^+^, and CD133^−^CD44^−^ subpopulations.

Statistical analyses
--------------------

Each mentioned experiment was performed at least three times. Differences between groups were analyzed using the Student's *t*-test. Correlation between gene expressions was compared through Pearson's correlation. Statistical analyses were performed using SPSS version 18.0 (SPSS Inc, Chicago, IL, USA). All analyses were considered statistically significant at *P*\<0.05(\*).

Results
=======

The expression of AC105461.1 was down-regulated in CRC tissue samples
---------------------------------------------------------------------

The expression of AC105461.1 was assessed by a panel paired specimen obtained from 47 CRC patients. The results indicated that the expression of AC105461.1 was significantly downregulated in CRC tissue samples ([Figure 1](#f1-ott-10-2367){ref-type="fig"}, \**P*\<0.05).

AC105461.1 expression was correlated with DIS3L2 in CRC tissue samples
----------------------------------------------------------------------

To identify the relationship between AC105461.1 and DIS3L2, we assessed the correlation of their expression levels in a group of 47 CRC patients using real-time PCR. For every sample, lncRNA was separated from cancerous tissues and adjacent nontumorous CRC tissues. The results illustrated that the expression of AC105461.1 was correlated with that of DIS3L2 in CRC tissue samples ([Figure 2](#f2-ott-10-2367){ref-type="fig"}, *R*=0.485, *P*\<0.001).

The expression of AC105461.1 was assessed in different CRC cell lines
---------------------------------------------------------------------

Through real-time PCR, we explored AC105461.1 expression in five CRC cell lines (SW480, HT29, HCT116, Caco-2, and SW620). The results demonstrated that the expression of AC105461.1 was highest in SW480 and lowest in SW620 cells ([Figure 3](#f3-ott-10-2367){ref-type="fig"}, \**P*\<0.05). Hence, SW620 and SW480 cells were respectively selected as our candidate cell lines for AC105461.1 overexpression and knockdown experiments.

Coregulation of DIS3L2 expression with AC105461.1 overexpression or knockdown in CRC cell lines
-----------------------------------------------------------------------------------------------

In the overexpression experiment, pcDNA-AC105461.1 and pcDNA control were conducted and transfected into SW620 cells. The results indicated that AC105461.1 expression was markedly elevated and DIS3L2 expression level was also apparently upregulated by pcDNA-AC105461.1 ([Figure 4A](#f4-ott-10-2367){ref-type="fig"}, \**P*\<0.05).

In the knockdown experiment, AC105461.1 siRNA and NC-si were respectively transfected into SW480 cells. Quantification PCR analysis showed that AC105461.1 expression level in AC105461.1 siRNA group was significantly knocked down in SW480 cells. Similarly, DIS3L2 expression level was also markedly decreased ([Figure 4B](#f4-ott-10-2367){ref-type="fig"}, \**P*\<0.05). Consequently, we could roughly speculate that the DIS3L2 expression may be modulated by AC105461.1.

AC105461.1 overexpression impaired the CSC properties
-----------------------------------------------------

In this section, the effect of AC105461.1 overexpression on stem cell-like properties in vitro was investigated in SW620 cells. Cell proliferation assay was conducted by transfecting pcDNA-AC105461.1 and NC plasmid into SW620 cells. The results showed that cell growth of SW620 cells in pcDNA-AC105461.1 was evidently slower than that in pcDNA-NC ([Figure 5A](#f5-ott-10-2367){ref-type="fig"}, \**P*\<0.05). The matrigel invasion assay conducted in SW620 cells exerted significant cell invasion inhibition in pcDNA-AC105461.1 compared with pcDNA-NC ([Figure 5B and C](#f5-ott-10-2367){ref-type="fig"}, \**P*\<0.05). Additionally, spheroid formation assay revealed that the spheroid formation rate in pcDNA-AC105461.1 was obviously slower compared with that in pcDNA-NC ([Figure 5D and E](#f5-ott-10-2367){ref-type="fig"}, \**P*\<0.05). Furthermore, flow cytometric analysis was conducted to further identify the influence of AC105461.1 overexpression on the CRC-CSCs properties. CD133 and CD44 were selected as the surface markers of CRC in our study. We found that the percentage of CD133^+^CD44^+^ in pcDNA-AC105461.1 group (2.01%) was low when compared with pcDNA-NC group (12.10%) ([Figure 5F](#f5-ott-10-2367){ref-type="fig"}). Taken together, these results suggested that AC105461.1 overexpression could impair the CSC properties.

AC105461.1 knockdown enhanced the CSC properties
------------------------------------------------

In this section, we determined the effect of AC105461.1 knockdown on stem cell-like properties in vitro in SW480 cells. Cell proliferation assay was conducted by transfecting AC105461.1 siRNA group and NC-si into SW480 cells. The results illustrated that cell growth of SW480 cells in AC105461.1 siRNA group was markedly higher than that in NC-si ([Figure 6A](#f6-ott-10-2367){ref-type="fig"}, \**P*\<0.05). Meantime, the matrigel invasion assay also showed significant cell invasion enhancement in AC105461.1 siRNA group in contrast to the NC group in SW480 cells ([Figure 6B and C](#f6-ott-10-2367){ref-type="fig"}, \**P*\<0.05). In addition, spheroid formation assay demonstrated that the spheroid formation rate in AC105461.1-si1 was obviously higher than that in NC-si ([Figure 6D and E](#f6-ott-10-2367){ref-type="fig"}, \**P*\<0.05). Flow cytometric analysis was also performed to observe the impact of AC105461.1 knockdown on CRC-CSCs properties. We observed that the percentage of CD133^+^CD44^+^ in AC105461.1 siRNA group was 4.39% and that in NC-si group was 0.96%, which illustrated that AC105461.1 knockdown enhanced the percentage of CD133^+^CD44^+^ ([Figure 6F](#f6-ott-10-2367){ref-type="fig"}). These results indicated that AC105461.1 knockdown could enhance the CSC properties.

Discussion
==========

Recent studies have proved that the lncRNAs have an impact on cancer development.[@b20-ott-10-2367],[@b21-ott-10-2367] LncRNAs expression and their functional mechanisms have aroused great attention in cancer diagnosis and treatment.[@b22-ott-10-2367] Emerging studies identify that some well-known cancer-related lncRNAs, such as lncRNA-ATB,[@b23-ott-10-2367] lncRNA-CLMAT3,[@b24-ott-10-2367] and lncRNA-H19,[@b25-ott-10-2367] are also involved in the tumor progression of CRC.

AC105461.1 is the antisense transcript of DIS3L2. A new study has demonstrated that DIS3L2 is a new component of the Lin28/let-7 pathway and also relevant to Perlman syndrome and cancer.[@b17-ott-10-2367] Additionally, King et al[@b18-ott-10-2367] and Tu et al[@b19-ott-10-2367] reported that Lin28 could promote colon cancer progression and metastasis by upregulating stem cell-related genes or cooperating with WNT signaling. Moreover, it has been revealed that transcriptions of most lncRNA genes are coordinated with that of adjacent protein-coding genes.[@b15-ott-10-2367] Intriguingly, AC105461.1 and DIS3L2 could form "lncRNA/mRNA gene pair", which have impact on each other in expression and function and also are closely associated with stem cell properties.[@b15-ott-10-2367]

In the present study, we firstly investigated whether the expression of AC105461.1 was down-regulated in CRC tissue samples. Next, we explored the expression patterns of the lncRNA/mRNA gene pair between AC105461.1 and DIS3L2 in 47 CRC specimens by real-time PCR. The results showed that the expression of AC105461.1 was positively correlated with that of DIS3L2 in CRC tissue samples. In order to select the appropriate cell lines, we investigated the expression of AC105461.1 in five different CRC cell lines. SW620 and SW480 cells were selected as our candidate cell lines for AC105461.1 overexpression and knockdown experiment, respectively. According to the AC105461.1 overexpression experiment, we found that AC105461.1 expression was markedly elevated in SW620 cells and DIS3L2 expression level was also apparently upregulated. Meantime, the results obtained by the AC105461.1 knockdown experiment suggested that AC105461.1 expression level in AC105461.1 siRNA group was significantly knocked down in SW480 cells and DIS3L2 expression was also markedly decreased. These results made us speculate that the DIS3L2 expression may be modulated by AC105461.1.

Currently, only a small number of CSC-like properties of CSC-related lncRNAs have been investigated.[@b12-ott-10-2367] Herein, cell proliferation assay, matrigel invasion assays, and spheroid formation as well as flow cytometry analysis were implemented to analyze the effect of AC105461.1 overexpression or knockdown on stem cell-like properties in vitro. We found that AC105461.1 overexpression impaired the CSC properties while knockdown enhanced the CSC properties, including self-renewal, migration, and invasion abilities. To further identify the influence of AC105461.1 expression on CRC-CSCs properties, CD133 and CD44 markers were selected to perform the flow cytometry analysis. The results indicated that overexpressed AC105461.1 reduced the percentage of CD133^+^CD44^+^ while knockdown showed the opposite effect. To our knowledge, this study may provide the first evidence that AC105461.1 is likely to negatively correlate with tumor progression. In addition, further studies declare that DIS3L2 is strongly linked with Lin28/let-7 pathway which is relevant to various cancers.[@b17-ott-10-2367],[@b26-ott-10-2367],[@b27-ott-10-2367] The need for further analyses of the exact regulation mechanism and the relationship between AC105461.1 and Lin28/let-7 pathway are unmet. We will perform the relevant experiments in our future study.

Conclusion
==========

Collectively, our data suggest that AC105461.1 may serve as a regulator of DIS3L2 and a mediator of CSCs in CRC. Furthermore, it could be a potential biomarker and therapeutic target for CRC. Certainly, further work targeting the exact regulation mechanism and the relationship between AC105461.1 and Lin28/let-7 pathway in CRC will be of great significance in the clinical cancer research.
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![The expression of AC105461.1 was down-regulated in CRC tissue samples (\**P*\<0.05).\
**Abbreviations:** CRC, colorectal cancer; T, tumor; N, normal.](ott-10-2367Fig1){#f1-ott-10-2367}

![AC105461.1 expression was correlated with DIS3L2 (*P*\<0.001).](ott-10-2367Fig2){#f2-ott-10-2367}

![AC105461.1 expression levels were assessed by real-time PCR in five cell lines (\**P*\<0.05).\
**Abbreviation:** PCR, polymerase chain reaction.](ott-10-2367Fig3){#f3-ott-10-2367}

![Coregulation of DIS3L2 expression with AC105461.1 overexpression or knockdown in CRC cell lines. (**A**) Overexpression experiment showed that AC105461.1 expression was markedly elevated and DIS3L2 expression level was also apparently upregulated by pcDNA-AC105461.1 in SW620 cells. (**B**) Real-time PCR analysis showed that the expressions of both AC105461.1 and DIS3L2 in AC105461.1 siRNA group were significantly knocked down in SW480 cells (\**P*\<0.05).\
**Abbreviations:** CRC, colorectal cancer; pcDNA, plasmid complementary DNA; real-time PCR, real-time quantitative polymerase chain reaction; NC, negative control; si, small interfering.](ott-10-2367Fig4){#f4-ott-10-2367}

![AC105461.1 overexpression impaired the CSC properties. (**A**) Cell proliferation assay showed that cell growth of SW620 cells in pcDNA-AC105461.1 was evidently slower than that in pcDNA-NC (\**P*\<0.05). (**B**, **C**) The matrigel invasion assay conducted in SW620 cells exerted significant cell invasion inhibition in pcDNA-AC105461.1 compared with pcDNA-NC (\**P*\<0.05). (**D**, **E**) Spheroid formation assay revealed that the spheroid formation rate in pcDNA-AC105461.1 was obviously slower compared with that in pcDNA-NC (\**P*\<0.05). (**F**) Flow cytometric analysis suggested that the percentage of CD133^+^CD44^+^ in pcDNA-AC105461.1 group (2.01%) was low when compared with pcDNA-NC group (12.1%).\
**Abbreviations:** CSC, cancer stem cell; pcDNA, plasmid complementary DNA; NC, negative control.](ott-10-2367Fig5){#f5-ott-10-2367}

![AC105461.1 knockdown enhanced the CSC properties. (**A**) Cell proliferation assay illustrated that cell growth of SW480 cells in AC105461.1 siRNA group was markedly higher than that in NC-si (\**P*\<0.05). (**B**, **C**) The matrigel invasion assay also showed significant cell invasion enhancement in AC105461.1 siRNA group in contrast to the NC group in SW480 cells (\**P*\<0.05). (**D**, **E**) Spheroid formation assay demonstrated that the spheroid formation rate in AC105461.1-si1 was obviously higher than that in NC-si (\**P*\<0.05). (**F**) Flow cytometric analysis showed that the percentage of CD133^+^CD44^+^ in AC105461.1 siRNA group is 4.39% and that in NC-si group is 0.96%, which illustrated that AC105461.1 knockdown enhanced the percentage of CD133^+^CD44^+^.\
**Abbreviations:** CSC, cancer stem cell; NC, negative control; si, small interfering.](ott-10-2367Fig6){#f6-ott-10-2367}

###### 

Clinicopathological characteristics of patients with CRC

  Age (years)   Sex   Tumor location   T stage   N stage   M stage   Pathological tumor type   Differentiation
  ------------- ----- ---------------- --------- --------- --------- ------------------------- -----------------
  50            F     Colon            T2        N0        M1        Adenocarcinoma            High
  71            M     Colon            T2        N0        M0        Adenocarcinoma            High
  60            M     Colon            T1        N0        M0        Adenocarcinoma            High
  62            F     Colon            T3        N0        M0        Adenocarcinoma            Medium
  76            M     Colon            T3        N1        M0        Adenocarcinoma            Medium
  50            F     Colon            T3        N2        M0        Adenocarcinoma            Medium
  39            F     Colon            T3        N0        M0        Adenocarcinoma            Medium
  51            F     Colon            T3        N0        M0        Adenocarcinoma            Medium
  76            M     Colon            T2        N0        M0        Adenocarcinoma            Medium
  41            M     Colon            T2        N2        M0        Adenocarcinoma            Low
  60            M     Colon            T3        N1        M1        Adenocarcinoma            Medium
  58            M     Colon            T2        N0        M0        Adenocarcinoma            Medium
  64            F     Colon            T4        N0        M1        Adenocarcinoma            Medium
  74            M     Colon            T3        N1        M0        Adenocarcinoma            Medium
  66            M     Colon            T3        N0        M0        Adenocarcinoma            Medium
  54            F     Colon            T2        N0        M0        Adenocarcinoma            Medium
  41            M     Rectum           T3        N0        M1        Adenocarcinoma            Low
  59            M     Colon            T4        N1        M1        Adenocarcinoma            Low
  36            M     Colon            T4        N1        M0        Adenocarcinoma            Low
  54            M     Colon            T3        N0        M0        Adenocarcinoma            Medium
  71            M     Rectum           T3        N1        M0        Adenocarcinoma            Medium
  42            M     Colon            T4        N2        M0        Adenocarcinoma            Low
  64            M     Colon            T3        N0        M0        Adenocarcinoma            Medium
  64            M     Colon            T3        N1        M1        Adenocarcinoma            Medium
  52            M     Terminal ileum   T3        N2        M0        Adenocarcinoma            Medium
  75            F     Colon            T3        N2        M1        Adenocarcinoma            Medium
  70            F     Rectum           T4        N0        M1        Adenocarcinoma            Medium
  61            M     Ileocecum        T4        N1        M0        Adenocarcinoma            Medium
  58            M     Colon            T3        N0        M0        Adenocarcinoma            Medium
  70            M     Rectum           T3        N1        M1        Adenocarcinoma            Medium
  45            F     Colon            T3        N0        M0        Adenocarcinoma            Low
  41            M     Colon            T2        N2        M0        Adenocarcinoma            Low
  52            M     Rectum           T3        N1        M1        Adenocarcinoma            Low
  39            M     Rectum           T1        N0        M0        Adenocarcinoma            Low
  73            F     Rectum           T4        N2        M0        Adenocarcinoma            High
  67            F     Colon            T3        N0        M0        Adenocarcinoma            High
  55            M     Rectum           T3        N2        M0        Adenocarcinoma            Low
  45            M     Rectum           T3        N0        M0        Adenocarcinoma            Medium
  48            M     Colon            T3        N2        M1        Adenocarcinoma            Medium
  70            M     Rectum           T3        N0        N0        Adenocarcinoma            Low
  51            F     Colon            T2        N1        M1        Adenocarcinoma            High
  53            M     Colon            T3        N1        M1        Adenocarcinoma            High
  48            F     Rectum           T3        N0        M0        Adenocarcinoma            Low
  56            M     Colon            T3        N2        M1        Adenocarcinoma            Medium
  66            F     Colon            T2        N2        M0        Adenocarcinoma            Medium
  55            F     Colon            T3        N1        M1        Adenocarcinoma            Medium
  49            F     Colon            T3        N2        M1        Adenocarcinoma            Medium

**Abbreviations:** CRC, colorectal cancer; M, male; F, female; T, tumor; N, lymph Node; M, metastasis.

###### 

Primers for real-time PCR analysis

  Gene name      Forward (5′--3′)         Reverse (5′--3′)
  -------------- ------------------------ -----------------------
  *DIS3L2*       ATGAGCCATCCTGACTACAGAA   AAGCACCAATGTCATGTGGAC
  *AC105461.1*   GCCTTCTGAAACATCCTCCTTG   CTCTTTTACCTCGCCTTGGG
  *GAPDH*        GAAGGTGAAGGTCGGAGTC      GAAGATGGTGATGGGATTTC

**Abbreviation:** PCR, polymerase chain reaction.

###### 

Sequences for small interfering RNA analysis

  Gene name          Sense (5′--3′)              Antisense (5′--3′)
  ------------------ --------------------------- -----------------------------
  *AC105461.1-si1*   CUCUGAGAUGAAUAAGGAAAAUUAC   GUAAUUUUCCUUAUUCAUCUCAGAGAA
  *AC105461.1-si2*   CAUAUUCUCUGAGAUGAAUAAGGAA   UUCCUUAUUCAUCUCAGAGAAUAUGAU

[^1]: These authors contributed equally to this work
